Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    10518505 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation
Conditions: Malignant Neoplasm of Stomach;   Effects of Chemotherapy
Interventions: Drug: Capecitabine/Cisplatin + Sorafenib;   Drug: Capecitabine/Cisplatin

Indicates status has not been verified in more than two years